Therefore, these data demonstrate that CIS treatment induces mesenchymal phenotype by VIM expression; this mechanism has been previously associated with chemoresistance (Li et al., 2011; Sun et al., 2012; Li et al., 2015). The gene discussed is VIM; the disease is in situ carcinoma.